However, even CD44+ cell enrichment has been reported in the majority of ovarian cancer samples after neoadjuvant therapy, no significant association with chemoresistance was reported and a decrease in CD44 expression was associated with shorter survival [49]. The gene discussed is CD44; the disease is ovarian cancer.